In ₹ Crore except Per Share Latest Annual | APLLTD FY26 | AJANTPHARM FY26 | IPCALAB FY26 | TORNTPHARM FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 23.80× | 41.88× | 43.84× | 77.05× | 43.84× -46% | |
| P/B | ◆ 2.83× | 9.80× | 5.25× | 9.48× | 9.48× -70% | |
| EV/EBITDA | ◆ 15.40× | 31.49× | 25.10× | 39.37× | 31.49× -51% | |
| Market Cap | ₹16,058 Cr | ₹44,374 Cr | ₹50,032 Cr | ₹1.67L Cr | ₹50,032 Cr -68% | |
| Growth | ||||||
| Revenue CAGR 3Y | 9.12% | 13.37% | ◆ 15.60% | 13.27% | 13.37% -32% | |
| Revenue CAGR 5Y | 6.37% | ◆ 13.54% | 12.22% | 11.80% | 12.22% -48% | |
| Net Income CAGR 3Y | 25.18% | 21.55% | ◆ 35.20% | 19.75% | 21.55% +17% | |
| Revenue YoY (latest Q) | 25.66% | 24.82% | 20.76% | ◆ 54.85% | 24.82% +3% | |
| Net Income YoY (latest Q) | 12.19% | 30.89% | ◆ 82.18% | 3.28% | 30.89% -61% | |
| Profitability | ||||||
| EBITDA Margin | 15.23% | 25.58% | 20.51% | ◆ 32.61% | 25.58% -40% | |
| Net Income Margin | 9.13% | ◆ 19.37% | 12.27% | 15.29% | 15.29% -40% | |
| Return on Common Equity | 11.83% | ◆ 23.33% | 11.98% | 12.30% | 12.30% -4% | |
| Return on Capital Employed | 12.97% | ◆ 25.78% | 15.51% | 9.56% | 15.51% -16% | |
| Return on Assets | 7.66% | ◆ 17.16% | 9.57% | 4.82% | 9.57% -20% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.24× | ◆ 0.05× | 0.07× | 0.84× | 0.07× +243% | |
| Interest Coverage | 8.54× | ◆ 75.83× | 20.55× | 8.94× | 20.55× -58% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹7,345 Cr | ₹5,453 Cr | ₹9,646 Cr | ₹13,980 Cr | ₹9,646 Cr -24% | |
| Net Income | ₹671 Cr | ₹1,056 Cr | ₹1,184 Cr | ₹2,138 Cr | ₹1,184 Cr -43% | |
| Total Assets | ₹8,763 Cr | ₹6,155 Cr | ₹12,370 Cr | ₹44,312 Cr | ₹12,370 Cr -29% | |
| EPS | ₹34.33 | ₹84.53 | ₹44.98 | ₹63.92 | ₹63.92 -46% | |
| Book Value per Share | ₹288.42 | ₹361.16 | ₹375.41 | ₹519.56 | ₹375.41 -23% | |